Disease Diagnosis TRIZ Cases

This case uses histone and proADM measurements to replace subjective ICU scoring with faster, objective organ failure assessment.

An antibody-based proUGN assay supports sensitive CKD detection, staging, and monitoring of kidney dysfunction treatment.

LDL-TG and ApoE-rich HDL-C measurements support noninvasive NASH detection and progression assessment without liver biopsy.

A multi-marker blood panel supports early detection, progression monitoring, and treatment-response prediction for Alzheimer’s disease.

Flow cytometry quantifies hemoglobin in individual erythroid cells, revealing distributions that support tailored sickle cell treatment.

Phenotype-specific binding proteins support Z-AAT and M-AAT detection, simplifying AATD diagnosis for point-of-care testing.

Engineered 810D12 antibodies eliminate false positives in IGF-1R scoring, ensuring accurate patient selection for targeted ADC therapy.

Monoclonal antibodies detect MELK expression levels in cancer cells, resolving false positives from inadequate immunological specificity.

Proximity ligation assays recover lost interaction data from tissue samples, enabling precise cancer treatment selection without added assay complexity.

Culturing patient-derived hippocampal progenitor cells to monitor proliferation and apoptosis.

A biomarker panel detects silent brain infarcts and cognitive decline through blood analysis.

Segmenting diagnostic processes into independent biomarker detections improves accuracy while maintaining modular testing approaches.

Segmented antigen arrays with cleavable mass tags resolve throughput versus comparability trade-offs in autoantibody screening.

A simulated synovial fluid composition replicates patient-derived viscoelastic properties using cytokines and hyaluronic acid.

Time-resolved fluorescence spectra of thioflavin T replace costly antibody methods, reducing measurement time while maintaining identification accuracy.

Capture antibodies bind prion proteins while plasmin cleaves normal forms to isolate pathological variants for detection.

Immobilized antibodies detect free MUC1fs in blood plasma, overcoming the inability to quantify variants with different VNTR lengths.

Measuring polysialic acid in liquid biopsies differentiates aggressive from indolent cancers, reducing false positives and unnecessary invasive procedures.

Replacing complex imaging with serum autoantibody measurement resolves the trade-off between diagnostic accuracy and procedure complexity.

Analyzing specific antibody levels against deiminated variants identifies oxygen-deprivation injuries, resolving the lack of effective biomarkers for diagnosis.

Measuring urinary L-FABP biomarkers predicts acute kidney injury risk before surgery, overcoming delayed diagnosis from serum creatinine tests.

Targeting SMARCB1-deficient tumors with STING antagonists improves treatment efficacy.

A multiplexed immunoassay quantifies specific autoantibodies in biological samples to enable non-invasive disease assessment.

A diagnostic method using copeptin and procalcitonin biomarkers to detect respiratory tract infections.

Real-time metabolic monitoring tracks sperm energy status to determine optimal processing timing for artificial insemination doses.

Correcting free light chain levels by glomerular filtration rate resolves the contradiction between renal monitoring and infection prognosis.

Detect traumatic brain injury using salivary biomarkers via lateral flow assays, resolving the trade-off between diagnostic accuracy and patient invasiveness.

A plasma assay detects p217+tau peptides using capture and detection antibodies to quantify tau levels in blood samples.

Mass spectrometry detects complement proteins after endoproteinase GluC digestion produces distinct peptides.

Segmenting genetic and metabolite pathways resolves diagnostic precision gaps in heterogeneous Charcot-Marie-Tooth cases without invasive procedures.

Replacing radioactive methods with a proinsulin sandwich assay improves diagnostic reliability and sensitivity for Type 1 diabetes prediction.

Segmenting monocyte populations via imaging flow cytometry improves detection sensitivity for SMA diagnosis while reducing required blood sample volumes.

Blood-based CTAP III and haptoglobin biomarkers reduce false positives in lung cancer screening by filtering high-risk patients before spiral CT scans.

Optical absorption spectroscopy detects hemoglobin variants through bathochromic and hypochromic shifts in oxygenated versus deoxygenated blood spectra.

Detecting immunoglobulins against biomarkers like RAB11B predicts anti-TNF treatment response, reducing wasted costs from ineffective therapies.

Girdin knockout mice exhibit spontaneous hippocampal epilepsy, allowing reliable MTLE drug screening via simple video analysis instead of complex EEG.

Quantitating soluble Semaphorin 4D levels in blood samples guides immunotherapy administration decisions.